The QualityStocks Daily Tuesday, February 27th, 2024

Today's Top 3 Investment Newsletters

Schaeffer's(JANX) $49.7500 +229.47%

360 Wall Street(VKTX) $85.0500 +121.02%

QualityStocks(SRAFF) $0.1250 +95.31%

The QualityStocks Daily Stock List

Sandfire Resources America (SRAF)

We reported earlier on Sandfire Resources America (SRAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sandfire Resources America Inc. (OTCQB: SRAFF) (CVE: SFR) is a mining exploration and development firm that is focused on acquiring, exploring for and developing resource properties in Canada and the United States.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1998, on July 30th. Prior to its name change in January 2018, the firm was known as Tintina Resources Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves mining industries in the U.S. and Canada.

The company is an 86.9% subsidiary of Sandfire Resources Ltd. It explores for copper, cobalt, zinc, lead, and silver deposits. Its flagship property is its 100% owned Black Butte copper project located in central Montana, the United States. The property contains sediment-hosted zones of massive sulfide mineralization. The drilling encountered significant zones of strata-bound copper sulfide with cobalt in multiple bedded pyrite zones in the lower part of the Precambrian Belt Super group. It is made up of approximately 7,684 acres of fee-simple lands and 4,541 acres in 239 Federal unpatented lode-mining claims. The Black Butte Copper Project is located approximately 17 miles north of White Sulphur Springs and includes the Johnny Lee Deposit, which contains a copper concentration. It uses state-of-the-art technology and modern techniques to mine high-grade copper.

The firm, which recently released its latest financial statements, remains focused on safeguarding its ability to continue pursuing the sourcing and exploration of its resource properties. This may in turn help create value for its shareholders.

Sandfire Resources America (SRAF), closed Tuesday's trading session at $0.125, up 95.3125%, on 2,739,166 volume. The average volume for the last 3 months is 18,852 and the stock's 52-week low/high is $0.04/$0.125.

Armata Pharmaceuticals (ARMP)

TradersPro, FreeRealTime, StockMarketWatch, QualityStocks and MarketBeat reported earlier on Armata Pharmaceuticals (ARMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Armata Pharmaceuticals Inc. (NYSE American: ARMP) (FRA: TG1N) is a biotechnology firm that is engaged in developing targeted bacteriophage therapeutics for treating antibiotic-resistant infections across the globe.

The firm has its headquarters in Marina del Rey, California and was incorporated in 2019, on May 9th. It operates as part of the pharmaceutical industry, under the health care sector, in the biotech and pharma sub-industry and mainly serves consumers in the state of California.

The company is focused on improving human health by developing new synthetic and natural bacteriophage-based treatments using 2 platforms, namely peptides and synthetic phages, which will help prevent infectious ailments of the microbiome and treating multidrug-resistant bacterial infections. It is party to a partnership agreement with Merck & Co. which entails the development of synthetic phage candidates that target infectious disease agents. The company was formed as a result of a merger between AmpliPhi Biosciences and C3J Therapeutics.

The enterprise’s product pipeline comprises of AP-PA03, which is indicated for the treatment of pneumonia; AP-PA02, which has been developed to treat Pseudomonas aeruginosa and AP-SA02, which is indicated for the treatment of Staphylococcus aureus bacteremia. Each of the enterprise’s product candidates is a combination of several chosen phages, which target a particular disease-causing bacterial pathogen.

The firm recently appointed a new CEO who has extensive drug development experience and will play a key role in positioning the firm as a leader in the field, which will not only have a positive effect on the company’s growth but also its investments.

Armata Pharmaceuticals (ARMP), closed Tuesday's trading session at $3.53, up 18.0602%, on 45,613 volume. The average volume for the last 3 months is 23,636 and the stock's 52-week low/high is $1.0701/$5.2565.

Kingstone Companies (KINS)

QualityStocks, StreetInsider, MarketBeat, Zacks, Trading Concepts, The Street Report, StocksEarning, Short Term Wealth, Investors Alley and InvestorPlace reported earlier on Kingstone Companies (KINS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kingstone Companies Inc. (NASDAQ: KINS) is a holding firm that provides property and casualty insurance policies to individuals and small businesses.

The firm has its headquarters in Kingston, New York and was incorporated in 1886. Prior to its name change in July 2009, the firm was known as DCAP Group Inc. It operates as part of the insurance-property and casualty industry, under the financial services sector. The firm serves consumers in the United States.

The company primarily operates through its Kingstone Insurance Company subsidiary, which is a licensed property and casualty insurance firm that offers its insurance products in New Jersey, Connecticut, New York, Massachusetts and Rhode Island. It underwrites its business utilizing industry claims databases, insurance scoring reports, physical inspection of risks and other individual risk underwriting tools. The company writes homeowners and dwelling fire business in coastal markets.

The enterprise provides personal line of insurance products, including homeowners and dwelling fire multi-peril, renters, cooperative/condominiums, and personal umbrella policies. It also offers canine legal liability policies; for-hire vehicle physical damage only policies for livery and car service vehicles and taxicabs; as well as reinsurance products. It sells its products through retail and wholesale agents and brokers.

The firm recently announced its latest financial results, with its CEO noting that they were well-positioned to better manage their risks on an efficient platform. It remains committed to driving profitability and enhanced value for its shareholders, which will in turn bolster the firm’s overall growth.

Kingstone Companies (KINS), closed Tuesday's trading session at $3.55, up 16.3934%, on 40,486 volume. The average volume for the last 3 months is 925,539 and the stock's 52-week low/high is $1.045/$3.75.

National Vision Holdings (EYE)

MarketBeat, Schaeffer's, MarketClub Analysis, InvestorPlace, Zacks, Trading Concepts, Market Intelligence Center Alert, The Street, StreetInsider, Trades Of The Day, InsiderTrades, StockMarketWatch, Daily Trade Alert, Smartmoneytrading, BUYINS.NET and QualityStocks reported earlier on National Vision Holdings (EYE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

National Vision Holdings Inc. (NASDAQ: EYE) is among the biggest optical retailers in the U.S. With more than 1100 outlets in 44 states across America as well as Puerto Rico and the District of Columbia, National Vision Holdings operates different brands under two segments. These include Vista Optical inside Fred Meyer stores and America’s Best Contacts and Eyeglasses, which are hosted and own segments and Vision Centers in select Walmart stores, which is a legacy segment. Apart from this, the firm also operates the Eyeglass World Brand.

This optical retail firm, which was founded in 1990, was sold to KKR & Co. in 2014. National Vision Holdings also supports Vista Optical military operations and owned brands by developing Omni-channel offerings. In addition to this, the firm, which offers various services and products that cater to all individuals’ eye care needs, such as a vision care benefit plan and health maintenance organization, has established a standalone commerce business.

Headquartered in Duluth, Georgia, National Vison Holdings, which provides safety eyewear, eyeglasses, contact lenses and frames, ensures that they develop quality eye wear and eye care that is easily accessible and affordable. Additionally, the company owns First Sight, a subsidiary that helps provide optometric services in nearly all optometric stores that are located near Sam’s Club and Walmart stores in the state of California.

In the recent months, the firm’s stock has grown by 58% and while its earnings have decreased in the past, analysts expect that in the future, the company’s earnings will grow tremendously. The recent increase in demand of affordable eye wear and eye care during the pandemic has enabled the company to expand further, which allows them to build their market share.

The firm, which occupies the largest optical market in America, has a good payout ratio and a high rate of profit retention, which makes it a good investment option. The company trades under the ticker symbol “ EYE” on NASDAQ.

National Vision Holdings (EYE), closed Tuesday's trading session at $23.11, up 15.7816%, on 3,085,238 volume. The average volume for the last 3 months is 6,996 and the stock's 52-week low/high is $13.71/$39.42.

Aptorum Group (APM)

RedChip, QualityStocks, MarketClub Analysis, Red Chip, MarketBeat, InvestorPlace, StreetInsider, StockMarketWatch and BUYINS.NET reported earlier on Aptorum Group (APM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aptorum Group Limited (NASDAQ: APM) (FRA: A1V) is a pharmaceutical firm that is focused on discovering, developing and commercializing therapies for treating various ailments, with a focus on cancers and infectious ailments.

The firm has its headquarters in London, in the United Kingdom and was founded in 2010, on September 13th by Ian Huen. It serves clients across the globe and operates in the healthcare sector, under the biotech and pharma sub-industry.

The company operates through the non-therapeutics and therapeutics segment. The former segment (non-therapeutics) is made up of diagnostics projects which include the sale of natural supplements, AML clinic and a new molecular-based rapid pathogen detection and identification diagnostic tool. On the other hand, the latter segment (therapeutics) is involved in the development of drug molecules and particular technologies for diagnosing and treating human diseases.

The enterprise’s pipeline is made up of various products, among them Claves, Nativus, RPIDD, Acticule and Smart-Act series. It has a few products in preclinical development, including DOI NLS-2, CLS-1, ALS-3, ALS-2, ALS-1 and ALS-4. Additionally, it has developed a product indicated for the treatment of neuroblastoma dubbed SACT-1 for the treatment of neuroblastoma. The enterprise is also centered on pursuing diagnostic projects and therapies in women’s health, metabolic disorders, gastroenterology, neurology and other areas. Furthermore, it has projects that center on natural supplements for women undergoing menopause and those who experience related symptoms as well as in surgical robotics.

The company recently entered into an agreement with Exeltis for the development and commercialization of a preclinical candidate that targets women’s health and gynecological conditions, and in particular endometriosis, which affects about 10% of women within the reproductive age. This product may help address unmet needs, which will be beneficial to the patients in need as well as the firm’s stakeholders.

Aptorum Group (APM), closed Tuesday's trading session at $1.64, off by 7.3185%, on 3,036 volume. The average volume for the last 3 months is 17,713 and the stock's 52-week low/high is $1.35/$9.00.

South32 (SHTLF)

StreetInsider reported earlier on South32 (SHTLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

South32 Limited (OTC: SHTLF) (ASX: S32) (LON: S32) (JSE: S32) (FRA: 32Z) is a diversified metals and mining firm focused on the production of alumina, bauxite, manganese, aluminum, copper, silver, lead, zinc, nickel, metallurgical coal, ferronickel, and other base metals.

The firm has its headquarters in Perth, Australia and was incorporated in 2000. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates through the Hillside Aluminum, Worsley Alumina, Mozal Aluminum, South Africa Energy Coal, Brazil Alumina, Eagle Downs Metallurgical Coal, Illawarra Metallurgical Coal, Australia Manganese, Hermosa, South Africa Manganese, Cerro Matoso, and Cannington segments. The Hillside Aluminum segment provides aluminum smelters at Richards Bay, South Africa while the Worsley Alumina segment offers bauxite mine and alumina refinery in Western Australia. The Mozal Aluminum segment includes aluminum smelter in Mozambique while the South Africa Energy Coal segment comprises of open-cut and underground energy coal mines and processing operations in South Africa. The Brazil Alumina segment covers alumina refinery in Brazil while the Eagle Downs Metallurgical Coal segment involves in the exploration and development of metallurgical coal deposits in Queensland, Australia. The Illawarra Metallurgical Coal segment comprises of underground metallurgical coal mines in New South Wales, Australia while the Australia Manganese segment is involved in the production of manganese ore in the Northern Territory and manganese alloys in Tasmania. On the other hand, the Hermosa segment is focused on the exploration and development option for zinc, lead and silver sulphide deposit in Tucson, United States. The South Africa Manganese segment produces ore and alloy in South Africa while the Cerro Matoso segment includes a laterite ferronickel mining and smelting complex in Colombia. The Cannington segment is focused on exploring for zinc, silver, and lead.

The firm remains committed to advancing exploration efforts at its properties, creating value for its shareholders and bolstering its overall growth.

South32 (SHTLF), closed Tuesday's trading session at $1.8275, even for the day, on 31,621 volume. The average volume for the last 3 months is 21.853M and the stock's 52-week low/high is $1.78/$3.23.

Alibaba Group Holding Ltd. (BABA)

InvestorPlace, The Street, Kiplinger Today, Schaeffer's, MarketClub Analysis, Money Morning, Zacks, StreetInsider, Trades Of The Day, Daily Trade Alert, Marketbeat, Market Intelligence Center Alert, StocksEarning, Investopedia, The Online Investor, Wealth Insider Alert, StreetAuthority Daily, ProfitableTrading, CustomerService,, TopStockAnalysts, Louis Navellier, Uncommon Wisdom, Early Bird, GorillaTrades, CNBC Breaking News, Cabot Wealth, Top Pros' Top Picks, StockEarnings, Profit Confidential, TipRanks, The Wealth Report, AllPennyStocks, Options Elite, Investors Alley, Total Wealth, Market Report, Money and Markets, Daily Profit, Street Insider, The Street Report, Barchart, Wyatt Investment Research, SmallCapVoice, StrategicTechInvestor, Investing Daily, Market Intelligence Center, Insider Wealth Alert, Daily Wealth, Average Joe Options, Power Profit Trades, Trade of the Week, Investing Signal, MarketTamer, INO Market Report, WStreet Market Commentary, Wealth Daily, Wall Street Daily, QualityStocks, The Best Newsletters, BUYINS.NET, MarketWatch, Short Term Wealth, Trader Prep, Trading Concepts, Inside Investing Daily, TheOptionSpecialist, FreeRealTime, InvestmentHouse, Visual Capitalist, 24/7 Trader, Rick Saddler, Dynamic Wealth Report, Investing Futures, Energy and Capital, Daily Dividends, Wealthpire Inc., The Weekly Options Trader, Investing Lab, Agora Financial, Investment U, OptionAlarm News, InvestorsHQ,, SureMoney, Shah's Insights & Indictments, Market Authority, Eagle Financial Publications, Summa Money, Dividend Opportunities, Direction Alerts, StockMarketWatch, Wallstreet Journal, Stock Gumshoe, The Trading Report, wealthmintrplus, Rockwell Trading, Beat The Street, Weekly Wizards, Navellier Growth, Atomic Pennies, wyatt research newsletter, 24-7 Stock Alert, SmallCapNetwork, Jim Cramer, The Night Owl, InvestorGuide, The Growth Stock Wire, Investment House, Investiv, The Stock Dork, Profits Run, InvestorsObserver Team, Energy & Resources Digest, Inside Trading,, Terry's Tips, TheoTrade, Hit and Run Candle Sticks, Greenbackers, Kiplinger’s Weekly Update, Goldman Small Cap Research, Liberty Through Wealth, Financial Freedom Post, Investor Guide and MarketDeal reported earlier on Alibaba Group Holding Ltd. (BABA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alibaba Group Holding Ltd. (NYSE: BABA) has revealed that it will focus its attention on its overseas business to bolster company performance amid sluggish domestic consumption growth. The company has experienced rising year-over-year losses in recent years, partly due to poor economic conditions in the domestic market.

China’s economy struggled to recover to pre-COVID levels after Beijing lifted coronavirus restrictions, leaving many critical sectors such as real estate in trouble. Several experts say the economic situation in the country is at a historic low. According to China Market Research Group founder Shaun Rein, China is currently experiencing record-low levels of consumer confidence. Rein predicts that economic conditions in China will be poor for the next three to six months.

Another analyst noted that deflation would soon start to impact Chinese economic growth, especially with Beijing looking forward to several months of a “very painful economy.” During a recent discussion with CNBC’s Squawk Box Europe, Rein said things in China were “really bad” and urged investors to be cautious.

Consequently, Alibaba is looking to shore up its bottom line by attempting to bolster foreign sales. The Chinese tech giant earned $4 billion from its international e-commerce unit in the December 2023 quarter, a sales increase of 44% from the prior year. This international business unit comprises platforms such as Lazada, AliExpress, Trendyol and Daraz. The foreign unit was the only bright spot in Alibaba’s most recent earnings report. Alibaba notes that its strong performance in the international market was driven by “solid growth” on all of  Alibaba International Digital Commerce Group’s retail platforms.

Alibaba also earned $18.1 billion from core e-commerce businesses Tmall Group and Taobao, a year-over-year increase of only 2%. Alibaba Group CEO Eddie Wu said the company will invest in improving user experiences on its platforms to increase growth for both Taobao and Tmall Group. He added that the company would use its resources to build public cloud products and maintain its growth momentum in the increasingly competitive international e-commerce stage. Alibaba’s recent earnings reports came after the company shuffled leaders at the parent company, as well as sister companies such as Lazada Group.

Southeast Asian e-commerce company Lazada Group carried out a mass layoff across most departments in early January. The layoffs affected everyone from retail and marketing to senior company management. Lazada Group CEO James Dong was also granted the position of acting CEO at Daraz in place of former CEO Bjarke Mikkelsen.

Alibaba Group Holding Ltd. (BABA), closed Tuesday's trading session at $77.68, up 1.5292%, on 14,490,200 volume. The average volume for the last 3 months is 1.373M and the stock's 52-week low/high is $66.63/$105.05.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report,, MarketClub Analysis, Uncommon Wisdom, Small Caps, PennyToBuck, StockHotTips, CRWEPicks, CRWEFinance, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, TraderPower, InsiderTrades, Schaeffer's, Broad Street, Awareness Stocks, PsychedelicNewsWire, StockOodles, Street Insider, The Street, TopPennyStockMovers and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent CNN report has highlighted how several athletes used psychedelics to overcome life-changing injuries and the myriad of mental-health challenges these injuries caused.

Canadian Daniel Carcillo began playing professional ice hockey after graduating high school and broke into the National Hockey League (NHL) by age 20. After a decade-long career that saw him play for the Los Angeles Kings, New York Rangers and Philadelphia Flyers, Carcillo was a two-time Stanley Cup winner on the cusp of a well-earned retirement.

However, he says, seven diagnosed concussions left him with headaches, anxiety, depression and “dementia-like” symptoms, rendering him suicidal. The retired hockey player says he also suffered from severe insomnia and disrupted sleep, spending nights awake and sleeping during the day.

Carcillo spent more than half a million dollars on prescription treatments and medications at brain centers, concussion centers and stroke rehabilitation centers but did not find any relief. He finally tried psilocybin in what he called a “last-ditch effort” and notes that he felt “the way he should” and had a zest for life for the first time in quite a long time.

A growing body of literature has connected various psychedelics with significant improvements in mental health, especially in patients suffering from conditions that are typically hard to treat. Harvard Health describes psychedelics as a class of drugs that can induce sensory perceptions and altered thoughts.

Some clinical studies have found that psilocybin, the main psychoactive agent in magic mushrooms, can produce significant and long-term changes in people with treatment-resistant major depressive disorder in only one or two doses.

Although most psychedelic research is still in preliminary stages, and researchers still don’t fully understand how psychedelics deliver their benefits, people are increasingly using drugs such as psilocybin (magic mushrooms), LSD and MDMA in place of traditional mental-health treatments.  However, experts say psychedelic use may be associated with potential risks, including heart rate abnormalities, high blood pressure and mental issues, such as psychosis.

NFL quarterback Aaron Rodgers is an outspoken supporter of the legalization of certain hallucinogenic drugs. He claims a psychedelic concoction called ayahuasca has helped boost his performance on the field. During last year’s Denver psychedelic conference, Rodgers said it was ironic how substances that could “expand your mind” are illegal, while more harmful substances have been “legal for centuries.”

Former boxing champion Mike Tyson has also spoken in favor of magic mushrooms, claiming they saved his life. Ultimate Fighting Championship (UFC) president Dana White noted in 2021 that the UFC would dive into researching the impact of psychedelic drug therapy on the brain health of its athletes.

As more companies such as atai Life Sciences N.V. (NASDAQ: ATAI) enter the psychedelic drug-development space, more is likely to be unveiled about how athletes and other groups of patients can benefit from different hallucinogenic compounds.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $2, up 5.2632%, on 1,030,984 volume. The average volume for the last 3 months is 591,898 and the stock's 52-week low/high is $1.025/$2.39.

Trulieve Cannabis Corp. (TCNNF)

InvestorPlace, QualityStocks, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Top Pros' Top Picks, Cabot Wealth, The Street, Trades Of The Day, Profit Trends, TradersPro, The Online Investor and StreetInsider reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A nonpsychoactive variant of cannabis called hemp is emerging as a renewable alternative to traditional building materials. Long before cannabis prohibition effectively banned the cultivation of all types of cannabis, hemp was used for centuries to make everything from clothes and ropes to sails and riggings in ships.

However, hemp cultivation and use in the United States was prohibited for several decades until Congress legalized the cannabis variant via the 2018 Farm Bill. With many states launching individual hemp programs in the years after, hemp has attracted significant attention because of its many potential applications.

One of the more revolutionary applications is using hemp as a renewable building block in building construction. Cement production produces around 8% of the world’s carbon dioxide emissions, making the sector one of the largest polluters on the globe. Using cement for construction also results in a host of issues because it creates unyielding surfaces with low insulation.

While the hunt for a large-scale cement replacement still hasn’t yielded any tangible possibilities, hemp presents the real-estate sector with a greener small-scale alternative. Mixing hemp hurds with either lime, pozzolans or sand creates a biocomposite breathable material called hemp-lime or hempcrete that can function as a small-scale alternative to cement.

Kaja Kühl, urban designer and founder of a New York-based design and building practice called youarethecity, says hemp fiber has “enormous growth potential” for construction and insulation in North America. She took part in a Columbia University initiative to help institute environmental initiatives in the Hudson Valley and used hemp-lime to complete two cottages on an upstate New York farm.

Since hemp-lime blocks aren’t load bearing, they are typically used to provide efficient thermal insulation and construct interior walls. Kühl used timber and prefabricated hempcrete bricks to design cottages with reduced carbon impact on the Wally Farms in upstate New York. The urban designer notes that a growing number of fabricators, designers and advocates consider biobased construction materials such as hempcrete as a means of reducing the upfront carbon footprint of traditional building materials.

Hemp has shown that it can capture more than twice its weight in carbon two times as fast as conventional forestry, allowing the cannabis variant to capture a whopping 15 tons of carbon dioxide per hectare via photosynthesis. If 25% of all the agricultural land used for livestock and dairy in the world is used for hemp cultivation, it would close the annual UN emissions gap of 23 gigatons of carbon dioxide.

Kühl says choosing carbon-sequestering materials such as hemp as construction materials could put the world on track to achieving carbon neutrality by mid-century.

As companies such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) focus on extracting medicinal products from the hemp and marijuana plant, new verticals are emerging that seek to make construction materials from what might otherwise be regarded as waste-plant matter.

Trulieve Cannabis Corp. (TCNNF), closed Tuesday's trading session at $9.75, off by 2.4083%, on 182,462 volume. The average volume for the last 3 months is 479,703 and the stock's 52-week low/high is $3.42/$11.96.

Green Thumb Industries Inc. (GTBIF)

InvestorPlace, QualityStocks, MarketBeat, Wealth Insider Alert, The Online Investor, Daily Trade Alert, Trades Of The Day, TradersPro, The Street, Cabot Wealth, CFN Media Group, StreetInsider, Zacks, Trading For Keeps, wyatt research newsletter, Kiplinger Today, Top Pros' Top Picks, Daily Profit and Technology Profits Daily reported earlier on Green Thumb Industries Inc. (GTBIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The legal status of cannabis remains complex in the United States, with the Drug Enforcement Administration (DEA) playing a central role. For years, the agency has maintained that cannabis is a highly dangerous and addictive drug and lacks medical value, despite contrary evidence from public opinion, medical research and state laws.

This has led to a situation where marijuana is readily accessible in certain states, heavily penalized in others and federally illegal throughout the country. According to Carmel Shachar, a professor at Harvard School of Law, the U.S. courts or Congress could resolve this confusion, but so far, there’s been limited action.

Currently, the DEA classifies cannabis as a Schedule I substance, alongside ecstasy, heroin and LSD. This classification indicates that the substances have a high addiction and abuse potential with no recognized medical benefits. Shachar points out the irony of cannabis being more restricted than substances such as morphine and cocaine, which are classified as Schedule II and acknowledged to have medical uses.

Marijuana’s Schedule I classification presents significant barriers to research into its potential medical benefits, creating a cycle where its value cannot be proven due to federal restrictions. Cannabis has remained under this classification since 1971, when it was initially added to the list under President Richard Nixon. According to experts, Nixon’s decision was influenced more by political motives than scientific evidence.

At the moment, the next potential development involves the DEA considering reclassifying cannabis to a lower schedule, though this wouldn’t federally legalize the substance. Advocates view this as a symbolic step in the right direction while also recognizing that it falls short of meaningful change.

Reclassification to Schedule III would allow for medical prescriptions but wouldn’t resolve the conflict between federal and state laws. To fully address this conflict, though still distant, cannabis would need to be removed from the Controlled Substances Act (CSA) altogether, according to experts. This means cannabis would be regulated in the same way as tobacco and alcohol.

National polls indicate that public support for cannabis legalization is high, with 70% of U.S. citizens in favor, according to a Gallup survey. Additionally, only 10% of people, according to a 2022 Pew Research Center poll, think the substance should be outlawed. By contrast, 30% favor legalization for only medical purposes, while 59% favor legalization for recreational and medical purposes.

Despite the overwhelming support, legalization progress is slow because of several factors, including differing opinions among legislators and concerns about potential health risks. As advocates note, while rescheduling is a positive step, it’s insufficient, and there’s no justification for marijuana to remain under federal regulation.

The cannabis industry, including entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), is focused on operating within the existing regulatory frameworks at state and federal level as it advocates for further reforms to be enacted.

Green Thumb Industries Inc. (GTBIF), closed Tuesday's trading session at $13, off by 4.7619%, on 282,413 volume. The average volume for the last 3 months is 39.937M and the stock's 52-week low/high is $6.42/$14.30.

Optec International Inc. (OPTI)

MarketClub Analysis, QualityStocks, OTCtipReporter, PennyStockProphet, Wall Street Resources, Penny Pick Finders, SmallCapVoice, Profitable Trader Authority, PennyStockScholar, Buzz Stocks, Fierce Analyst, Penny Stock General, Shiznit Stocks, StockOnion, StockWireNews, BeatPennyStocks, Small Cap Firm, MarketBeat, Make Penny Stocks Great Again, HotOTC, StockStreetWire, Epic Stock Picks, Damn Good Penny Picks and Penny Picks reported earlier on Optec International Inc. (OPTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RB Capital Partners, a judgment creditor against Optec International Inc. (OTC: OPTI), today announced its engagement of Mark Basile and The Basile Law Firm P.C. to work with the courts to officially appoint a receiver to run Optec in the interim while a new company is merged into the public vehicle. RB Capital, the largest investor and legitimate shareholder of Optec International, was forced to bring a shareholder derivative action against Optec to secure the company’s judgment, oust Roger Pawson and to try to preserve Optec’s assets. According to the announcement, the next step in the process is to officially appoint a receiver in order for the new management to obtain control of Optec/OPTI, the public vehicle, and ultimately access to OTC Markets via OTCIQ. “We are working very diligently with all parties involved to get this matter resolved as fast as possible so Optec can begin the next chapter of the company’s story,” said Brett Rosen, managing partner of RB Capital Partners. “In order to promote transparency, RB Capital commits to making consistent updates about Optec via press releases and social media posts. We could have easily just walked away with our judgement, but Deborah and I stayed and took on the responsibility of Optec so we can make this right for all those who were wronged by the former CEO’s actions.”

To view the full press release, visit

About RB Capital Partners Inc.

RB Capital Partners is a private investment fund headquartered and incorporated in California. The main investment focus of RB Capital is on small and microcap publicly traded companies trading on the OTC Markets, Nasdaq and New York Stock Exchange. RB Capital predominantly makes debt investments and is known for paying off any harmful convertible debt, giving companies a real chance at success. RB Capital Partners does NOT manage any outside money, nor does it have any investors. It is run and funded solely by Brett Rosen and Deborah Rosen who each have a 50% ownership stake in the company.

Optec International Inc. (OPTI), closed Tuesday's trading session at $0.0027, off by 22.8571%, on 117,354,262 volume. The average volume for the last 3 months is 56,262 and the stock's 52-week low/high is $0.0002/$0.0047.

PetVivo Holdings (PETV)

EmergingStockPlays, PennyStocks24, ExclusiveStockPick, QualityStocks, VipStockReports, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, Bull Trends, Pumps and Dumps, Jet-Life Penny Stocks, Penny Pick Insider, Penny Stocks VIP, Equity Observer, Wall Street Mover, Daily Stock Motion, PoliticsAndMyPortfolio, Planet Penny Stocks, PennyStockProphet, Penny Stocks Profile, PennyStockShark, Penny Pick Finders, OTCBB Journal, Michael Stone, HotStockProfits, Growing Stocks Reports, First Penny Picks, Featured PS Report, Epic Stock Picks, DSR News, Club Penny Stocks Network, Buzz Stocks, MajorPennyStocks, Stock News Now, Value Penny Stocks, Wallstreetbuzz, Trading Wall St, Research Driven Investor, Research Driven Alerts, Super Hot Penny Stocks, Hot Stock Profits, Super Nova Stock Picks, InvestorSoup, JackpotStock Picks, TopPennyStockMovers, Goldman Small Cap Research, FOX Penny Stocks, Fortune Penny Stocks, SuperStockTips, The Lotto Pick, Greenbackers, Trades Of The Day, Super Hero Stocks, USA Market News, LuckyStockPicks, Email Stock Picks, Damn Good Penny Picks, Wallstreet Profiler, WePickPennyStocks, Winning Penny Stock Picks, Breaking Bulls, Blaque Capital Stocks, Beacon Equity Research, AwesomeStocks, EpicVIP Group, Penny Stock Pick Alert, Psycho Penny Stocks, PREPUMP STOCKS, RisingPennyStocks, SecretStockPromo, SixFigureStockPicks, SMS Penny Picks, PennyStock PayCheck, PennyStock MarketBulls, PennyPickAlerts, Xtreme Stock Picks, Stock Preacher, Ascending Stocks, Joe Penny Stocks, Penny Stock Pick Report, PennyDoctor, Penny Stock Newsletter, Penny Stock MoneyTrain, Penny Stock Craze, Penny Picks, Stock Roach, StockHideout, StockMister, StockOnion, Orbit Stocks, StockProfessors, StocksImpossible, RagingStock Bull, LiquidTycoon and Penny Stocks Finder reported earlier on PetVivo Holdings (PETV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PetVivo Holdings (NASDAQ: PETV, PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets, announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. According to the announcement, effective beginning at 10:00 a.m. ET on March 5, 2024, PetVivo to commence trading on Upstream under the ticker symbol PETV. The dual listing is designed to provide PetVivo the opportunity to access a global, digital-first investor base outside the U.S. that can trade using credit, debit, PayPal, USD, or USDC; unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in PetVivo.

To view the full press release, visit

About PetVivo Holdings Inc.

PetVivo Holdings is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of 21 patents protects the company’s biomaterials, products, production processes and methods of use. The company’s lead product SPRYNG(TM) with OsteoCushion(TM) technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats dogs and horses, is currently available for commercial sale. For more information about PetVivo and its revolutionary product, Spryng with OsteoCushion Technology, please contact or visit or

PetVivo Holdings (PETV), closed Tuesday's trading session at $1.18, even for the day, on 12,206 volume. The average volume for the last 3 months is 4,598 and the stock's 52-week low/high is $0.55/$3.60.

The QualityStocks Company Corner

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate Energy, a publicly traded distributed energy solutions company, just announced its strategic partnership with Carbonsight, an online decarbonization planning tool

With the partnership, Correlate will empower building portfolio owners with the tools and resources that allow them to make easier informed decisions toward decarbonization

Move also complements Carbonsight's mission of providing businesses with financially viable and environmentally sustainable solutions

Correlate Energy (OTCQB: CIPI), a publicly traded company strategically positioned to capitalize on America's unstoppable trend toward decentralized energy generation, just announced its strategic partnership with Carbonsight (by Autocase). This move brings together Carbonsight's cutting-edge decarbonization planning software and Correlate's expertise in developing and financing renewable and clean energy projects, together helping businesses transition to a low-carbon future (

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Tuesday's trading session at $1.43, even for the day. The average volume for the last 3 months is 169,003 and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market

The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes

This is timely, given Lexaria's resolve to double down on GLP-1 investigations for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules - per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.4, up 6.1947%, on 706,887 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.35/$.

Recent News

Sigyn Therapeutics Inc. (OTCQB: SIGYD)

The QualityStocks Daily Newsletter would like to spotlightFathom Sigyn Therapeutics Inc. (OTCQB: SIGYD).

Sigyn's common stock, temporarily trading under the ticker symbol "SIGYD", is set to revert back to its historic symbol "SIGY" on February 29, 2024.

The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health.

During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company's cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM).

The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a strategic competitive advantage within the dialysis industry.

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released its year-end 2023 financials and additionally disclosed the completion of a 1-for-40 reverse split of its common stock was implemented on January 31, 2024. As a result of this split, Sigyn's common stock will trade under the ticker symbol "SIGYD" for 20 business days and revert to trading under its historic symbol "SIGY" on February 29, 2024.

Sigyn Therapeutics Inc. (OTCQB: SIGYD) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy™ to address pathogen-associated inflammatory disorders, the ImmunePrep™ platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep™ to improve the delivery of cancer chemotherapy and ChemoPure™ to reduce the toxicity of chemotherapy.

Sigyn created each of these technologies with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in healthcare, and 2) their successful clinical advancement would offer a potential competitive advantage to established therapeutic organizations.

Sigyn Therapy™

The company is advancing Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia and sepsis, which is the leading cause of hospital deaths in the United States.

The technology has the following attributes and capabilities.

  • Sigyn Therapy™ incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.
  • In vitro studies have demonstrated the ability of Sigyn Therapy™ to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, 12 relevant targets, including viral pathogens, bacterial toxins and inflammatory cytokines, were validated. Subsequent animal studies were completed at the University of Michigan.
  • Sigyn Therapy™ is highly efficient, as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.
  • To allow for broad deployment, Sigyn Therapy™ is designed for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

First-in-human studies of Sigyn Therapy™ plan to enroll dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. There are more than 550,000 individuals with ESRD in the United States, which result in approximately 85 million dialysis treatments being administered each year.

The ImmunePrep™ Platform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation: they are poorly delivered to cancer cell targets, and, as a result, a majority of patients do not respond to therapy.

The Sigyn team recognized that just a small fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered by circulating decoys that display the target (antigen) binding site of the antibody. In response, Sigyn designed the ImmunePrep™ platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody.

The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefit.

The opportunity to enhance the performance of therapeutic antibodies is significant. Consider that Pfizer’s $43 billion acquisition of Seagen Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023, with anticipated revenues of ~$24 billion.

ChemoPrep™ and ChemoPure™

Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep™ to overcome a delivery limitation of the most commonly administered drug to treat cancer.

The company is developing ChemoPrep™ to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery. High concentrations of tumor exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations of tumor exosomes correspond with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients. Based on these factors, the company believes there is a compelling scientific rationale to reduce the circulating presence of tumor exosomes prior to chemotherapy administration.

Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure™ to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream. The company believes that a reduction in chemotoxicity may also alleviate treatment-related fatigue and potentially temper the long-term health consequences associated with chemotherapy administration.

Management Team

James A. Joyce is Co-Founder, Chairman and CEO of Sigyn Therapeutics. He has more than two decades of public company CEO and corporate board leadership experience and is an inventor or co-inventor of 20 pending or issued patents, including those underlying ImmunePrep, ChemoPrep, ChemoPure and Sigyn Therapy. Previously, he was founder and CEO of Aethlon Medical, a therapeutic technology company that he built from a start-up to a Nasdaq-traded company. Under his leadership, Aethlon developed the first medical device to receive two breakthrough device designations from the FDA. Mr. Joyce graduated from the University of Maryland.

Annette Marleau, Ph.D., is Chief Scientific Officer at Sigyn Therapeutics. Prior to joining the company, she was Chief Technology Officer at Immunicom Inc. and Director of Research at Aethlon Medical Inc. Additionally, she is an inventor on pending and issued patents underlying blood purification therapies targeting cancer, inflammatory disorders and life-threatening infectious diseases. She holds a Ph.D. from Western University, an M.S. from the University of Guelph and a B.S. from the University of Waterloo in Canada.

Jerry DeCiccio, CPA, is CFO at Sigyn Therapeutics. He has more than 40 years of financial industry experience. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications and President at Cerebain Biotech Corp. He also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc. and Newport Corp. He earned a bachelor’s degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California.

Sigyn Therapeutics Inc. (OTCQB: SIGYD), closed Tuesday's trading session at $5, off by 4.7619%, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.08/$19.20.

Recent News

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000

The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world's first mass spectrometer-based explosive trace detectors ("ETD"), to customers in Romania

Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp.

The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for the three months ended December 31, 2023 ("Q2 2024").

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.


Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Tuesday's trading session at $7.74, up 3.7534%, on 2,837 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

By 2060, the older Asian population in the U.S. is expected to reach 8.5 million, making up 9% of the country's elderly demographic, signaling a significant increase from 4% in 2014

Astiva Health is leading the charge in creating essential healthcare solutions tailored for this expanding demographic, demonstrating a deep understanding of their unique healthcare needs

Astiva Health has introduced groundbreaking programs, including language-specific healthcare services and wellness initiatives, specifically designed for the diverse aging Asian American community

Astiva Health is working serve the Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the population requiring more healthcare and support. The company is proactively meeting the unique needs of this rapidly aging group by providing healthcare services that are culturally sensitive and honor the diverse traditions and values across Asian cultures.

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News



The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Japan's cabinet has approved a bill that would allow limited liability partnerships (LLPs) including venture capitalist (VC) firms to invest in Web3 cryptocurrency tokens. Called the Industrial Competitiveness Enhancement Act, the measure is meant to advance the creation of new business and investment in Japan's industries. If the legislation passes, it would loosen Japan's strict VC cryptocurrency investment rules and finally grant Web3 startup firms that only issue cryptocurrencies access to venture capitalist funding. Local media reported that the national cabinet approved certain revisions to the proposed measure such as adding cryptocurrency assets to the list of assets that can be acquired by investment business limited partnerships (LPS). Investment business limited partnerships are funds that typically invest in unlisted startups and companies. Japan is a leader in cryptocurrency regulation and one of the most forward economies in Web3 and blockchain technology. The East Asian nation has one of the largest volumes of real-world asset (RWA) tokenization compared to other nations, particularly in the real estate sector. As Japan is taking steps to enable the entry of VCs into the Web3 investment arena, several North American companies, such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), are already leveraging a number of Web3 applications to enhance their e-commerce services to clients.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.455, off by 2.3555%, on 28,508 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.3701/$4.26.

Recent News


The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, is partnering with TráTek Monitoring Services to expand its footprint in Canada. The company announced that TráTek, which is based in British Columbia, has signed an agreement to adopt its SOBRsafe technology for use in its family law practice with voluntary pretrial clients. In conjunction with the agreement, TráTek has purchased multiple SOBRcheck(TM) and SOBRsure(TM) devices. TráTek has become a licensed channel partner of alcohol monitoring technologies and works to support the legal system across Canada. According to the announcement, the company plans to deploy SOBRsafe solutions nationwide through its regional sales manager model; TráTek is also evaluating SOBRsafe technology for potential use the Canadian over-the-road trucking market.

According to a TráTek official, SOBRsafe technology is much easier to use, delivers faster results and is less expensive for the user than current options. "This relationship with TráTek accomplishes two key goals for SOBRsafe: 1) it gets our technology in immediate live use in Canada, and 2) it places motivated ‘boots on the ground' for us across all provinces at no upfront or fixed costs to SOBRSafe," said SOBRsafe chair and CEO Dave Gandini in the press release. "We feel that TráTek is an ideal organization for growing our brand and business interests in Canada."

To view the full press release, visit

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.


The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.


With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.


SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.


SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.


Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Tuesday's trading session at $0.6348, off by 2.3535%, on 28,036 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004/$2.53.

Recent News

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Diamond Lake Minerals (OTC: DLMI), a multi-strategy operating company that specializes in the development and support of digital assets and SEC-registered security tokens, was featured in the most recent edition of the Corporate Investment Times. The article, titled "Pioneering the Future of Digital Assets and Security Tokens," discusses a profound transformation in the financial world driven by the emergence of tokenization. In this new realm, "visionaries such as Larry Fink of BlackRock and Jonathan Larsen of Ping A Global Voyager Fund foresee a future where digital assets traded on innovative protocols revolutionize transactions… where settlements occur instantaneously, and fees plummet, all made possible by sidestepping traditional clearing and settlement procedures. Yet, beyond efficiency, transparency emerges as a cornerstone in this evolving landscape. Advanced technologies like zero-knowledge proofs tantalize with the promise of verification sans exposure of sensitive data, thereby enhancing security and trust within the system. Envision validating transactions without divulging private information, crafting a financial network that is both secure and streamlined," the piece reads.

"In embracing this transformative paradigm, Diamond Lake Minerals Inc. (DLMI) emerges as a beacon of innovation. Established in Salt Lake City, UT, USA in 1954, the company has undergone a metamorphosis from a pioneer in mineral exploration to a trailblazer in SEC-registered security tokens. This steadfast commitment to innovation underscores DLMI's determination to navigate the ever-shifting terrain of finance and technology. In their own words, they aspire to reintroduce ‘timeless business principles focused on healthy sustainable growth, robust earnings that yield returns, all within a modern digital framework, thereby creating value for our stakeholders.'"

To view the full article, visit

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

  • Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
  • Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
  • Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
  • Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
  • Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
  • IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
  • Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
  • Technology: DLMI plans to back pioneers driving the next tech revolution.
  • Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
  • Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
  • Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
  • Education: DLMI collaborates with platforms revolutionizing learning through tech.
  • Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
  • Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
  • TV: DLMI intends stakes in TV platforms innovating content delivery.
  • Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
  • Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
  • Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
  • IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
  • Data Management: DLMI seeks ventures optimizing data utilization and insights.
  • Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
  • Streaming: DLMI intends to back streaming platforms prioritizing user experience.
  • Real World Assets: DLMI eyes investments translating tangible assets into digital value.
  • Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
  • Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
  • Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
  • Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
  • Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
  • Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
  • Studio Production: DLMI’s vision includes support for studios transforming content creation.
  • Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
  • Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
  • Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
  • Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
  • Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
  • Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
  • Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
  • Space Economy: DLMI targets investments in ventures monetizing space exploration.
  • Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
  • Financial Technology: DLMI seeks partnerships modernizing financial transactions.
  • Gaming: DLMI aims to back game developers enhancing user immersion.
  • Travel: DLMI eyes collaborations transforming travel experiences through tech.
  • Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
  • Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
  • AI: DLMI seeks to support AI innovations humanizing tech interactions.
  • Esports: DLMI targets investments in platforms amplifying esports experiences.
  • Construction: DLMI plans to back ventures modernizing construction practices.
  • Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
  • Retail Tech: DLMI envisions collaborations digitizing retail experiences.
  • Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Tuesday's trading session at $4.2, off by 0.473934%, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$5.90.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) ("Fr8Tech"), a technology company whose custom-developed, industry leading Fr8App freight-matching platform offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today announced a significant collaboration with Envases Universales, one of the largest packaging companies worldwide. According to the announcement, Fr8App was awarded key routes through Envases' annual 2024 RFQ, underscoring its commitment to delivering exceptional transportation services and its capability to meet the evolving needs of its clients. "We are thrilled to have been chosen by Envases Universales to help manage their transportation needs over the coming year," said Fr8App's CEO Javier Selgas. "This collaboration not only speaks to our capabilities but also to the trust Envases Universales has in our ability to deliver exceptional service. It also highlights the importance of tactical collaboration between the companies in driving profitable growth and achieving excellence in dependable and efficient logistics execution."

To view the full press release, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $1.96, off by 4.8544%, on 901,165 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.86/$34.10.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB), a provider of secured solutions for e-Government, IoT and cybersecurity sectors, aims to revolutionize public safety worldwide through proprietary electronic monitoring technology, data intelligence and complementary services. "SuperCom's proprietary PureSecurity suite is an all-in-one, field-proven offender monitoring system, with services such as GPS monitoring, home detention, domestic violence prevention, and more. The suite is specifically tailored to meet each client's needs. By leveraging the power of AI, SuperCom's PureSecurity platform can offer new capabilities, such as amplified data analysis, predictive modeling and streamlined automation – geared toward optimizing decision making and operational efficiency… SuperCom's PureSecurity suite for electronic monitoring under court-ordered programs includes the company's GPS digital tracking platform PureTrack, the PureTag wearable RF bracelet, the PureOne one-piece tracking device, and the home-based PureCom station," a recent article reads. "Ordan Trabelsi, SuperCom's president and CEO, said that the company was uniquely positioned to capitalize on the increasing global demand for secured electronic monitoring solutions and is strategically investing in continuous improvement of its offerings, extending its reach into new markets, which is already yielding promising results in the U.S. and other regions."

To view the full article, visit

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More



In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.


Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Tuesday's trading session at $0.1735, off by 0.857143%, on 380,548 volume. The average volume for the last 3 months is 1.812M and the stock's 52-week low/high is $0.16/$1.9399.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS"), Parkinson's and multiple sclerosis ("MS"). "The company's lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of energy metabolism to enable dying neurons to resist the multiple stressors associated with disease, allowing them not only to survive but also to function," a recent article reads. The article discusses CNM-Au8 development pathways, which have included: a Phase 2 VISIONARY trial in MS; two Phase 2 brain imaging studies, REPAIR-MS and REPAIR-PD, in participants with MS and PD; RESCUE-ALS, a nine-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in early-stage ALS participants; and a HEALEY-ALS Platform trial, a six-month, Phase 2 study that investigated CNM-Au8 for efficacy and safety in participants with ALS. "During 2024, Clene will work with the U.S. FDA to consider the strength of Clene's data while exploring all potential pathways to commercialization, including the possibility of accelerated approval based upon a biomarker and/or survival signal. With the supportive efficacy data and additional biomarker data in the pipeline, the company believes that the development path for CNM-Au8 looks bright in 2024."

To view the full article, visit

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $0.425, off by 0.375059%, on 835,445 volume. The average volume for the last 3 months is 1.052M and the stock's 52-week low/high is $0.25/$1.44.

Recent News

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.


Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Tuesday's trading session at $1.34, up 0.75188%, on 47,183 volume. The average volume for the last 3 months is 131,377 and the stock's 52-week low/high is $1.21/$3.5734.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.